CSL Ltd Market Cap ($68.91 Billion)
Market Cap & Net Worth: CSL Ltd (CSL)
CSL Ltd market cap. CSL Ltd (AU:CSL) has a market capitalization of $68.91 Billion (AU$97.38 Billion) as of October 31, 2026. Listed on the AU stock exchange, this Australia-based company holds position #412 globally and #8 in its home market, demonstrating a 2.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CSL Ltd's stock price AU$200.73 by its total outstanding shares 485151394 (485.15 Million).
CSL Ltd Market Cap History (2015–2026)
CSL Ltd market cap history from 2015 to 2026. Data shows growth from $32.28 Billion to $68.91 Billion (8.79% CAGR). Check latest CSL Ltd stock price today for real-time trading data and today's change.
Index Memberships
CSL Ltd is a constituent of 9 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P/ASX 50
AFLI
|
$1.65 Trillion | 4.18% | #7 of 50 |
|
Australia All Ordinaries
AORD
|
$2.01 Trillion | 3.43% | #6 of 495 |
|
S&P/ASX 20
ATLI
|
$1.24 Trillion | 5.56% | #6 of 20 |
|
S&P/ASX 100
ATOI
|
$1.88 Trillion | 3.67% | #7 of 100 |
|
S&P/ASX All Australian 50
AXAF
|
$1.53 Trillion | 4.50% | #6 of 50 |
|
S&P/ASX All Australian 200
AXAT
|
$1.92 Trillion | 3.59% | #6 of 200 |
|
S&P/ASX 200
AXJO
|
$1.89 Trillion | 3.65% | #6 of 200 |
|
S&P/ASX 200 Accumulated
AXJOA
|
$1.89 Trillion | 3.65% | #6 of 200 |
|
S&P/ASX 300
AXKO
|
$2.16 Trillion | 3.19% | #7 of 300 |
Weight: CSL Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CSL Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CSL Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CSL Ltd (CSL) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
3.84x
CSL Ltd's market cap is 3.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
19.74x
CSL Ltd's market cap is 19.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $31.31 Billion | $6.06 Billion | $1.24 Billion | 5.17x | 25.20x |
| 2017 | $44.66 Billion | $7.02 Billion | $1.34 Billion | 6.36x | 33.39x |
| 2018 | $59.24 Billion | $7.46 Billion | $1.27 Billion | 7.94x | 46.55x |
| 2019 | $89.30 Billion | $8.32 Billion | $1.92 Billion | 10.74x | 46.54x |
| 2020 | $92.63 Billion | $9.41 Billion | $2.17 Billion | 9.85x | 42.63x |
| 2021 | $96.07 Billion | $10.33 Billion | $2.39 Billion | 9.30x | 40.19x |
| 2022 | $96.20 Billion | $10.49 Billion | $2.25 Billion | 9.17x | 42.67x |
| 2023 | $97.07 Billion | $13.17 Billion | $2.19 Billion | 7.37x | 44.24x |
| 2024 | $96.66 Billion | $14.69 Billion | $2.64 Billion | 6.58x | 36.59x |
| 2025 | $59.27 Billion | $15.43 Billion | $3.00 Billion | 3.84x | 19.74x |
Competitor Companies of CSL by Market Capitalization
Companies near CSL Ltd in the global market cap rankings as of October 31, 2026. See CSL Ltd net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to CSL Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
- Argen-X (BR:ARGX): Ranked #562 globally with a market cap of $47.46 Billion USD ( €40.60 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
| #562 | Argen-X | BR:ARGX | $47.46 Billion | €807.20 |
Market Capitalization of CSL Ltd (2015–2026)
Market capitalization of CSL Ltd from 2015 to today. Between 2015 and today, CSL Ltd's market cap moved from $32.28 Billion to $ 68.91 Billion, with a yearly change of 8.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$68.91 Billion | +16.26% |
| 2025 | AU$59.27 Billion | -38.69% |
| 2024 | AU$96.66 Billion | -0.42% |
| 2023 | AU$97.07 Billion | +0.91% |
| 2022 | AU$96.20 Billion | +0.13% |
| 2021 | AU$96.07 Billion | +3.72% |
| 2020 | AU$92.63 Billion | +3.72% |
| 2019 | AU$89.30 Billion | +50.75% |
| 2018 | AU$59.24 Billion | +32.64% |
| 2017 | AU$44.66 Billion | +42.66% |
| 2016 | AU$31.31 Billion | -3.02% |
| 2015 | AU$32.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of CSL Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $68.91 Billion USD |
| MoneyControl | $68.91 Billion USD |
| MarketWatch | $68.91 Billion USD |
| marketcap.company | $68.91 Billion USD |
| Reuters | $68.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CSL Ltd
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more